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ApoptosisThe formation of acellular capillaries in the retina, a hallmark feature of diabetic retinopathy, is caused by apopto-
sis of endothelial cells and pericytes. The biochemical mechanism of such apoptosis remains unclear. Small heat
shock proteins play an important role in the regulation of apoptosis. In the diabetic retina, pro-inﬂammatory
cytokines are upregulated. In this study, we investigated the effects of pro-inﬂammatory cytokines on small
heat shock protein 27 (Hsp27) in human retinal endothelial cells (HREC). In HREC cultured in the presence of cy-
tokine mixtures (CM), a signiﬁcant downregulation of Hsp27 at the protein and mRNA level occurred, with no
effect on HSF-1, the transcription factor for Hsp27. The presence of high glucose (25 mM) ampliﬁed the effects
of cytokines on Hsp27. CM activated indoleamine 2,3-dioxygenase (IDO) and enhanced the production of
kynurenine and ROS. An inhibitor of IDO, 1-methyl tryptophan (MT), inhibited the effects of CM on Hsp27. CM
also upregulated NOS2 and, consequently, nitric oxide (NO). A NOS inhibitor, L-NAME, and a ROS scavenger
blocked the CM-mediated Hsp27 downregulation. While a NO donor in the culture medium did not decrease
the Hsp27 content, a peroxynitrite donor and exogenous peroxynitrite did. The cytokines and high glucose-
induced apoptosis of HREC were inhibited by MT and L-NAME. Downregulation of Hsp27 by a siRNA treatment
promoted apoptosis inHREC. Together, these data suggest that pro-inﬂammatory cytokines induce the formation
of ROS andNO,which, through the formation of peroxynitrite, reduce theHsp27 content and bring about apopto-
sis of retinal capillary endothelial cells.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
According to the International Diabetes Federation, there were
311 million people with diabetes worldwide in 2011 and this number
is projected to increase to 552 million by 2030 [1]. One of the devastating
long-term complications of this disease is diabetic retinopathy, which is
the leading cause of visual impairment in working-class adults in the US
and other developed countries. In both type 1 and type 2 diabetes, diabet-
ic retinopathy becomes progressively worse with duration of the disease;cells; IDO, indoleamine 2,3-
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logy and Visual Sciences, Case
y Building, 301, 2085 Adelbert
ights reserved.it is estimated that after 20 years of diabetes, nearly 75% of patients show
clinical signs of the disease [2].
Vascular, glial and neuronal abnormalities are the earliest changes in
the diabetic retina [3,4]. Retinal capillary cells become increasingly
permeable to macromolecules, leading to macular edema. The extracel-
lular matrix of capillary cells becomes thicker and localized sacular
microaneurysms develop on capillaries. Along with these changes,
pericytes and endothelial cells, the two cell types in retinal capillaries,
die early in the disease, causing formation of acellular capillaries that
lead to local ischemia in the retina [reviewed in [5]]. A number ofmech-
anisms have been put forward to explain these histopathological chang-
es, including pro-inﬂammatory signals [reviewed in [6]]. Chronic
low-grade inﬂammation appears to play a role in the pathogenesis of
the disease [7,8].
Several pro-inﬂammatory cytokines, such as tumor necrosis factor-
α (TNF-α), interleukin-1β (IL-1β) and interferon-γ (IFN-γ), are elevat-
ed in the diabetic retina [9–11]. These cytokines upregulate nuclear
factor-kappaB (NF-κB),which, in turn, can promote the synthesis of cyto-
kines [12]. Along with these changes, inﬂammatory markers, including
vascular cell adhesion molecule-1 (VCAM-1), intracellular adhesion
molecule-1 (ICAM-1), nitric oxide synthase-2 (NOS2), cyclooxygenase-2
(COX2), and monocyte chemotactic protein-1 (MCP-1), are upregulated
in the diabetic retina [reviewed in [6]].
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tion in diabetic retinopathy. These include a demonstration that phar-
macological suppression of inﬂammation leads to inhibition of ICAM-1
expression and leukostasis (attachment of leukocytes to endothelial
cells, a characteristic feature of inﬂammation) and that the absence of
TNF-α leads to suppression of blood retinal barrier breakdown in dia-
betic retina [13,14]. In addition, the inhibition of caspase-1, which acti-
vates IL-1β, inhibits capillary degeneration [15], and the inhibition of
NF-κB leads to inhibition of ICAM-1 and vascular endothelial growth
factor-A production in the diabetic retina [16]. Finally, the inhibition of
COX2 and NOS2 blocks capillary cell death and reduces leukostasis
and blood retinal barrier breakdown, respectively, in the retinas of dia-
betic rodents [17,18].
Despite clear evidence of an increased inﬂammatory response in di-
abetic retinopathy, the source(s) of inﬂammatory cytokines in the reti-
na are unclear. While capillary cells can produce cytokines in small
amounts, it is believed that retinal glia, Muller cells and microglia, as
well as retinal pigmented epithelial cells, are capable of producing
these cytokines. Cellular stresses, such as endoplasmic reticulum stress
and stress imposed by ROS, promote the synthesis of cytokines [8,19];
however, it remains unclearwhether these cells synthesize inﬂammato-
ry cytokines in response to hyperglycemia in diabetes or through
hyperglycemia-driven processes. Nevertheless, there is a clear link
between inﬂammation and capillary cell death in experimental diabetic
retinopathy and in cultured retinal capillary cells. Despite these advances,
the exact mechanism by which inﬂammation brings about apoptosis of
retinal capillary cells remains unknown. It has been suggested that ROS,
produced from activated NADPH oxidase and leakage of electrons from
the mitochondrial electron transport chain, and nitric oxide, produced
from upregulated NOS, are involved, but the actual mechanism is largely
unknown. We also demonstrated that IFN-γ upregulates indoleamineFig. 1. Individual cytokines do not affect Hsp27 levels in HREC. HREC cultureswere incubatedw
(C) for 48 h. Hsp27 was measured by Western blotting and densitometry. The bars represent
Cont = Control.2,3-dioxygenase (IDO) through the JAK/STAT pathway in human retinal
endothelial cells, leading to the formation of kynurenines, which sponta-
neously produce ROS [20].
Small heat shock proteins are ubiquitously present in cells and they
protect cells from stresses through their chaperone, anti-apoptotic and
anti-inﬂammatory activities. This family is composed of more than
10 members [21], among which αA- and αB-crystallin and Hsp27 are
present in retinal cells [22–25]. Both αB-crystallin and Hsp27 have
been implicated in angiogenesis [26,27]. Despite these ﬁndings, wheth-
er there are alterations in their levels in capillary cells in diabetes is un-
known. In this study, we investigated the effects of pro-inﬂammatory
cytokines and high glucose on Hsp27 expression and present data to
show that downregulation of this protein leads to apoptosis of human
retinal endothelial cells.
2. Materials and methods
1-Methyl-DL-tryptophan, DETA NONOate [2,2′-(hydroxynitro-
sohydrazino)bis-ethanamine], L-NAME (Nω-nitro-L-arginine methyl
ester hydrochloride), 1-oxyl-2,2,6,6-tetramethyl-4-hydroxypiperidine
(TEMPOL), DL-kynurenine, and D-glucose were obtained from Sigma-
Aldrich Chemical Co. LLC (St. Louis, MO, USA). TNF-α and IL-1β were
obtained from Invitrogen (Grand Island, NY). IFN-γwas obtained from
R and D systems (Minneapolis, MN). N-Acetyl-Asp-Glu-Val-Asp-7-
amido-4-triﬂuoromethylcoumarin (Ac-DEVD-AFC)was from BD Biosci-
ences, San Jose, CA. The peroxynitrite donor, 3-morpholinosydnonimine
(SIN-1) was obtained from Acros Organics, NJ. Peroxynitrite was
from Calbiochem, EMD Biosciences, San Diego, CA and 5-(and-6)-
chloromethyl-2′,7′-dichloroﬂuorescein diacetate, acetyl ester (CM-
D2DCFDA) was fromMolecular Probes, Eugene, OR. All other chemicals
were of analytical grade.ith 10 and 20 ng/mL TNF-α (A), 10 and 20 ng/mL IL-1β (B), and 50 and 100 U/mL of IFN-γ
means ± SD of three independent experiments. GAPDH was used as the loading control.
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Human eyes from 46 to 55 year-old donors without systemic dis-
eases were obtained from the National Disease Research Interchange
(Philadelphia, PA). Human tissue research adhered to the tenets of the
Declaration of Helsinki. HREC were isolated and cultured using a previ-
ously publishedmethod [28]. The cellswere characterized by their char-
acteristic uptake of DiI-Ac-LDL (acetylated low density lipoprotein,
labeled with 1,1′-dioctadecyl-3,3,3′,3′-tetramethyl indocarbocyanine
perchlorate) and CD31 staining and were found to be 95–99% pure.
Cells in passage numbers between 3 and 8were used in all experiments.
They were grown in six-well plates, coated with 0.1% gelatin, in
Dulbecco's modiﬁed Eagle's medium/F12, supplemented with 10%
fetal bovine serum, 5% endothelial cell growth supplements, 1% penicil-
lin/streptomycin and 1% insulin-transferrin-selenium at 37 °C in hu-
midiﬁed 95% air/5% CO2. All experiments were conducted with cells
that had attained 60–70% conﬂuency.
For individual cytokine treatment, HREC were cultured with TNF-α
(10 or 20 ng/mL), IL-1β (10 or 20 ng/mL) or IFN-γ (50 or 100 U/mL)
for 48 h without replacing the medium. For cytokine mixture (CM)
treatment, HREC were incubated with two combinations of cytokines
(CM1 = 10 ng/mL of TNF-α + 10 ng/mL of IL-1β + 50 U/mL of IFN-
γ or CM2 = 20 ng/mL of TNF-α + 20 ng/mL of IL-1β + 100 U/mL of
IFN-γ) with or without 25 mM D-glucose for 48 h without replacing
the medium. To study the effect of kynurenine, cells were cultured
with 100 μM DL-kynurenine for 48 h without replacing the medium.
To determine the role of indoleamine 2,3-dioxygenase (IDO), we
added an inhibitor of IDO, 1-methyl-DL-tryptophan (MT), at 20 μM,
with or without cytokines to the culture medium and cells wereFig. 2.CMandHGdownregulateHsp27 inHREC.HREC cultureswere incubatedwith cytokinem
TNF-α, 20 ng/mL IL-1β and 100 U/mL of IFN-γ for 48 h. Hsp27 was measured by Western blo
presence of high glucose (HG, 25 mMglucose) further downregulated both Hsp27 protein (B) a
tion. Hsp27 phosphorylation at S82, assessed byWestern blottingwas also reduced by CM ± HG
used as the loading/internal control. The bars represent means ± SD of three independent expe
iments. *p b 0.05, **p b 0.005 and ***p b 0.0005, versus control. Cont = Control.incubated for 48 h. In other experiments, to determine the role of nitric
oxide (NO), cells were incubated for 48 h with a nitric oxide synthase
inhibitor, L-NAME at 500 μM or a nitric oxide donor DETA NONOate at
500 μM. For peroxynitrite treatment, culture media was replaced with
PBS, and peroxynitrite was added at 200 μM concentration. Cells were
then incubated for 20–30 min, after which PBS was replaced with cul-
ture media; the cells were subsequently incubated for 0, 24 or 48 h.
To determine the effect of ROS and NO on Hsp27, we added TEMPOL
(100 μM) and L-NAME (500 μM), respectively, along with inﬂammato-
ry cytokines. We also tested the role of peroxynitrite by adding a
peroxynitrite donor, SIN-1, to serum-free medium at 1 or 2 mM and
cells were incubated for 3 h, followed by culturing for an additional
48 h in the complete media.
2.2. SDS-PAGE and Western blot analysis
Trypsinized cells were lysed with Mammalian Protein Extraction
Reagent (M-PER, fromThermo Scientiﬁc, Rockford, IL) containing a pro-
tease inhibitor cocktail (1:100; Sigma, St. Louis, MO). Protein concentra-
tion was determined using the BCA Protein Assay Kit with BSA as the
standard (Thermo Scientiﬁc). HREC proteins were resolved by SDS-
PAGE, and Western blotting was carried out with 10 μg cell lysate
protein, using one of the following antibodies: Hsp27 mAb (1:1000 di-
lution, Cell Signaling Technologies, Danvers, MA), p(S82)Hsp27 mAb
(1:1000 dilution, Cell Signaling), NOS2 mAb (1:1000 dilution, BD
Biosciences, San Jose, CA), HSF-1 pAb (1:1000 dilution, Cell
Signaling) or αB-crystallin (1:1000 dilution, Enzo Life Sciences,
Farmingdale, NY). Secondary antibodies were HRP-conjugated goat
anti-mouse (1:5000 dilution) or goat anti-rabbit antibody (1:5000ixtures, CM1 = 10 ng/mLTNF-α, 10 ng/mL IL-1β and50 U/mL IFN-γ or CM2 = 20 ng/mL
tting and densitometry. CM downregulated Hsp27 protein (A) and mRNA (C) and in the
ndmRNA levels (D). HG alone showed a slightly lower but statistically insigniﬁcant reduc-
(E). In all ﬁgures, representativeWestern blots/gels are shown at the top left.β-Actinwas
riments, but in the case of pHsp27 they representmean values of two independent exper-
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luminescence Detection Kit (Thermo Scientiﬁc). The membrane was
re-probed for the loading control with an antibody for GAPDH
(1:1000 dilution, Millipore, Billerica, MA), histone H3 (1:1000 dilu-
tion, Cell Signaling Technologies) or β-actin (1:1000 dilution, Cell
Signaling Technologies).2.3. RT-PCR analysis of Hsp27 and HSF-1
RNAwas extracted from cells using the RNeasy mini kit and RT-PCR
was carried out using the One step RT-PCR Kit (Qiagen). The following
forward and reverse primers were used: Hsp27-FP-5′-ATG ACC GAG
CGC CGC GTC CCC TTC TC-3′, RP-5′-TTA CTT GGC GGC AGT CTC ATC
GGA TT-3′, HSF-1-FP-5′-ACA GCA TCA GGG GCA TA-3′, RP-5′-ATG GCC
AGC TTC GTG CG-3′ and β-actin-FP-5′-CAG CTC ACC ATG GAT GAT
GAT-31 RP-5′-CTC GCC CGT GGT GGT GAA GCT-3′.
PCR products were visualized by electrophoresis in ethidium
bromide-stained 1% Agarose gels with the β-actin ampliﬁcation as the
loading control.2.4. Measurement of ROS and nitrite levels
ROS were measured as described previously using 5-(and-6)-
chloromethyl-2′,7′-dichlorodihydro-ﬂuorescein diacetate (CM-
H2DCFDA) [29]. Nitrite levels were measured in media using Measure-
IT High-Sensitivity Nitrite Assay Kit (Invitrogen, Grand Island, NY)
according to the manufacturer's instructions. Samples were read in aFig. 3. CMdoesnot downregulate or functionally impairHSF-1. Cellswere cultured and treatedw
Similarly, HSF-1 protein levels were unaltered (C). Cells were fractionated into cytosolic and nu
(E) fractions were unchanged by CM and HG treatments. In all ﬁgures, representative Western
were used as the loading/internal control. The DNA binding of HSF-1was assessed by an EMSA
HG, lane 5, treated with CM1 + HG and lane 6, treated with CM2 + HG. The DNA binding of HSpectramax Gemini XPS spectroﬂuorometer (Molecular Devices,
Sunnyvale, CA) at excitation/emission wavelengths of 365/450 nm.
2.5. Measurement of IDO activity
IDO activity was measured by HPLC, as described previously [29].
Brieﬂy, 50 μg of lysatewas added to the reactionmixture (50 mMsodium
phosphate buffer pH 6.5, 20 mM ascorbic acid sodium salt, 200 μg/mL
bovine pancreatic catalase, 10 μM methylene blue and 400 μM
L-tryptophan) and incubated at 37 °C for 1 h. After stopping the reac-
tion with 30% TCA, the samples were incubated at 65 °C for 15 min to
convert N-formyl kynurenine to kynurenine. The reaction mixture
was analyzed by HPLC for the product, kynurenine.
2.6. Measurement of kynurenines
Kynurenines were measured by HPLC, as described previously [29].
For these measurements 50 μg protein from HREC lysate was used.
2.7. Electrophoretic mobility shift assay
Electrophoretic mobility shift assay for HSF-1 was carried out using
the Light Shift Chemiluminescent EMSA Kit (Thermo Scientiﬁc) accord-
ing to the manufacturer's instructions. HREC were treated with
CM ± HG or peroxynitrite, as above. Cytosolic and nuclear extracts
were separated using NE-PER nuclear and cytosolic extraction reagents
(Thermo Scientiﬁc). Nuclear extract corresponding to 2.5 μg protein
was used for the assay. The following biotinylated probe and itsith cytokines as in Fig. 2. HSF-1mRNA levelswere unaffected byCM(A) or CMandHG (B).
clear fractions andWestern blotted for HSF-1. HSF-1 levels in the cytosolic (D) and nuclear
blots/gels are shown at the top left. β-Actin for cytosolic and histone for nuclear proteins
(F). Lane 1, control, lane 2, treatedwith CM1, lane 3, treatedwith CM2, lane 4, treatedwith
SF-1 was similar in all treatments. Arrow indicates DNA-bound HSF-1. FP = free probe.
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AAG GGC TGG ACC GTC GGC T-3′.
2.8. Cell treatment with Hsp27 siRNA
HRECs were treated with control or Hsp27 siRNA (Cell Signaling
Technologies) according to the manufacturer's instructions. Transfec-
tion was carried out with the Lipofectamine RNAiMAX Transfection Re-
agent (Invitrogen, Grand Island, NY). Transfection was conﬁrmed after
24 h with ﬂuorescein-conjugated control siRNA by ﬂorescence micros-
copy (data not shown). Apoptosis was measured as below. Western
blotting was carried out to conﬁrm the downregulation of Hsp27 in
HREC.
2.9. Overexpression of Hsp27 in HREC
Human Hsp27 was cloned into pcDNA 3.1 vector as previously de-
scribed [30] Plasmid DNA (2.5 μg) was transfected into HREC (1 × 105
cells) using Superfect Transfection Reagent following the manufac-
turer's protocol (Qiagen, Valencia, CA). Hsp27 overexpression was con-
ﬁrmed by Western blotting. Transfected cells were treated with CM1
and CM2 ± HG for 48 h as above. Apoptotic cells were quantiﬁed
after staining with Hoechst reagent (see below).
2.10. Measurement of apoptosis
After the treatments described above, cells were washed with PBS,
ﬁxed in 4% paraformaldehyde and permeabilized with 80% methanol,
and apoptotic cells were detected by their fragmented chromatin after
staining with Hoechst 33258 reagent and counted using a ﬂuorescent
microscope. Caspase-3 activity in cell lysates (=10 μg protein) was de-
termined as previously described [29].Fig. 4. Downregulation of Hsp27 by CM is suppressed by an inhibitor of indoleamine 2,3-diox
activity (A) and kynurenines in cells measured by HPLC (B) were higher in the presence of CM a
determined byWestern blotting, were restored to control levels byMT treatment in cells treate
increased by HG (E). The ROS production (measured as ﬂuorescent derivatives) by CM was
subtracted from the values shown. Exogenous kynurenines (100 μM, Kyn) had no effect on
represent means ± SD of three independent experiments. Representative Western blots are
between MT treated and untreated in B and E.2.11. Statistical analysis
The results are given as means ± SD. Statistical signiﬁcance was
determined by two-tailed t-test. Values of p b 0.05 were considered to
indicate statistical signiﬁcance.
3. Results
3.1. Effects of individual cytokines on Hsp27 in HREC
To determine whether individual pro-inﬂammatory cytokines af-
fected Hsp27 levels in HREC, cells were treated with TNF-α, IL-1β or
IFN-γ for 48 h. None of the cytokines, at the two concentrations tested,
had any effect on the level of Hsp27 (Fig. 1).
3.2. CM and high glucose (HG) downregulate Hsp27 and its phosphoryla-
tion (ser82) in HREC
Because all three cytokines are simultaneously elevated in the dia-
betic retina, we tested whether a combination of cytokines would
have an effect on the expression and phosphorylation of Hsp27. The
cells were treated with two concentrations of cytokine mixtures (CM1
and CM2). CM1 reduced the Hsp27 levels by 16% (relative to untreated
controls), which was further reduced signiﬁcantly by CM2 (p b 0.005,
Fig. 2A). We also tested a mixture of cytokines in which IFN-γ was
50 U/mL and the other two cytokines were each 20 ng/mL (CM3).
This combination of the cytokines also resulted in a signiﬁcant reduction
(p b 0.0005) in Hsp27 levels (Supplemental Fig. 1). To determine
whether high concentrations of glucose (to mimic diabetes conditions)
would inﬂuence the cytokine-mediated downregulation of Hsp27, cells
were treated with 25 mM of D-glucose (referred to as high glucose or
HG) along with cytokines. HG alone showed a slight but statisticallyygenase. Cultures of HREC were treated with CM, as in Fig. 2, along with 20 μMMT. IDO
nd increased further in the presence of HG, but inhibited byMT (open bars). Hsp27 levels,
d with CM (C) and in cells co-treatedwith HG (D). CM generated ROS in HREC, which was
largely inhibited by MT (open bars). In E, control values (cells alone or cells + MT) are
Hsp27 levels (F). β-Actin was used as the loading control in Western blotting. The bars
shown at the top of each ﬁgure. *p b 0.05 and ***p b 0.0005 relative to control in A, and
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was a signiﬁcant steep drop inHsp27 level (p b 0.005; Fig. 2B).We then
determinedwhether the downregulation of Hsp27 occurred at the tran-
scription level. RT-PCR analysis showed that CM reduced the Hsp27
mRNA levels (Fig. 2C). The effect was exacerbated when cytokines
were co-administered with HG (p b 0.0005; Fig. 2D). The downregula-
tion of Hsp27 was accompanied by reduced phosphorylation at S82
(pS82) of Hsp27 (Fig. 2E). HG alone also reduced Hsp27 phosphoryla-
tion. Together, these data suggest that under diabetic conditions, the
combined actions of HG and cytokines could markedly deplete Hsp27
and its phosphorylation in HREC, consistent with our previous data of
reduction of the rodent homolog, Hsp25 in the STZ-mouse model [31].
We also tested whether cytokines ± HG treatments as above altered
the αB-crystallin levels in HREC. Unlike Hsp27, αB-crystallin levels
were unaltered by CM ± HG treatments (Supplemental Fig. 2).
3.3. CM does not affect HSF-1 in HREC
HSF-1 is a transcription factor that regulates the expression of
Hsp27. The cytokines with or without HG did not signiﬁcantly affect
HSF-1 mRNA (Fig. 3A and B) or protein levels in HREC (Fig. 3C). We
then investigated whether CM and HG inhibited nuclear translocation
of HSF-1, which is necessary for the transcription of Hsp27. WeFig. 5. CMupregulates NOS2 and increasesNOproduction inHREC. HRECwere treatedwith CMas
culture medium (B). However, treatment with the NO donor, DETA NONOate increased NO lev
CM + HG + L-NAME are shown in E and F, respectively, and are similar, though L-NAME treatm
blots are shown at the top of each ﬁgure. β-Actin was used as the loading control in Western blotmeasured the HSF-1 content in the cytosol and nuclear fractions of
HREC by Western blotting. This analysis showed no difference in HSF-
1 content in the cytosolic or nuclear fractions (Fig. 3D, E). We then test-
ed whether HSF-1 binding to DNAwas negatively affected by CM using
an electrophoretic mobility shift assay, which showed that DNA binding
of HSF-1 was unaffected by the CM in the presence or absence of HG
(Fig. 3F). Together, these results indicate that the CM-mediated Hsp27
downregulation was not due to reduced expression, reduced nuclear
translocation, or decreased DNA binding of HSF-1.
3.4. CM upregulates indoleamine 2,3-dioxygenase (IDO) and increases the
ROS content in HREC
IDO is a cytosolic protein that catalyzes the degradation of trypto-
phan, and has been shown to be upregulated by inﬂammatory cyto-
kines. The CM upregulated IDO activity in HREC (Fig. 4A). HG
enhanced the effect of CM. Such activation led to the formation of
kynurenine (Fig. 4B), which is one of the cytotoxic oxidation products
of tryptophan.Whether the IDO-mediated kynurenine pathwaywas re-
sponsible for the downregulation of Hsp27 by the CMwas tested using
MT, an inhibitor of IDO. MT treatment inhibited kynurenine production
(Fig. 4B), and inhibited the CM-mediated Hsp27 downregulation
(Fig. 4C); this occurred even in the presence of HG (Fig. 4D). Sincein Fig. 2. Treatmentwith CMupregulatedNOS2 (A) and consequently NO (nitric oxide) in the
els (C) but had no effect on Hsp27 (D). Hsp27 levels in HREC treated with CM + L-NAME,
ent blocked the downregulation of Hsp27 in CM2 + HG samples. Representative Western
ting. Data are means ± SD of three independent experiments. *p b 0.05, ***p b 0.0005.
Fig. 6. Peroxynitrite downregulates Hsp27 in HREC. HREC were treated with a peroxynitrite donor (SIN-1, 1 and 2 mM) for 3 h (A) or peroxynitrite (200 μM) for 20 min, followed by in-
cubation for 0, 24 and 48 h (B). Peroxynitrite (200 μM) had no effect on HSF-1 level (determined by Western blotting) in the cytoplasm (C) or nucleus (D). EMSA (E) showed that
peroxynitrite treatment did not alter the nuclear binding of HSF-1. Lane 1, control, lanes 2 and 3 are from cells treated with ONOO• for 20 min and incubated 24 and 48 h, respectively.
Arrow indicates DNA-bound HSF-1. FP = free probe. Representative Western blots are shown at the top of ﬁgures. Data are means ± SD of three independent experiments. *p b 0.05.
Fig. 7. Inhibition of ROS and NO production normalizes Hsp27 levels CM-treated HREC. To determinewhether inhibition of NO and ROS products would restore Hsp27 to control levels in
CM treated cells (in the presence or absence ofHG), cellswere treatedwith 500 μMof aNOS inhibitor, L-NAME and 100 μMof a ROS scavenger, TEMPOL for 48 h (A). Hsp27wasmeasured
byWestern blotting and the densitometric data are shown. Data are means ± SD of three independent experiments. ROS levels were inhibited signiﬁcantly, and the levels were similar
among CM with or without HG samples (B). Nitrite levels in the culture media are shown in C. L-NAME and TEMPOL inhibited NO production with CM. ***p b 0.0005 between
(L-NAME + TEMPOL) and untreated cells.
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mediated kynurenine pathway was responsible for ROS production in
HREC. HG alone increased ROS levels, an effect that was exacerbated
by the addition of cytokines (Fig. 4E). This increase in ROSwas inhibited
by the addition of the IDO inhibitor, MT. We then tested whether
kynurenine alone (in the absence of cytokines) was responsible for
the downregulation of Hsp27. Our results showed that kynurenine
alone had no effect on the Hsp27 level (Fig. 4F). Together, these data
demonstrate that cytokine-mediated induction of IDO in HREC leadsFig. 8.CM induces apoptosis ofHREC throughdownregulationofHsp27.HREC cellswere treatedwi
with HG (B) induced apoptosis of HREC. Caspase-3 activity was measured in cell lysates (=10 μ
Hsp27, cells were treated with an siRNA or a scrambled siRNA for Hsp27 for 48 h; targeted siRN
induced apoptosis (E). Treatment with 20 μMMT for 48 h (F) or 500 μM L-NAME for 48 h (G) i
SIN-1, for 3 h also induced apoptosis in HREC (H). Data are means ± SD of three independent exto the formation of kynurenines, followed by ROS production during
downregulation of Hsp27, but ROS alone is not responsible for such
downregulation.
3.5. CM upregulates NOS2 and increases nitric oxide in HREC
Treatment of HREC with the CM resulted in the upregulation of
NOS2 (Fig. 5A). While CM1 increased NOS2 levels by ~14% over con-
trols, CM2 increased NOS2 levels by 21% (p b 0.05). The increase inthCMas in Fig. 2. ApoptosiswasmeasuredusingHoechst reagent. CM(A) and in combination
g protein) using a ﬂuorogenic substrate, Ac-DEVD-AFC (C). To determine the speciﬁc role of
A treatment reduced Hsp27 levels signiﬁcantly, as determined by Western blotting (D) and
nhibited apoptosis in CM ± HG treated cells. Treatment of cells with a peroxynitrite donor,
periments. *p b 0.05, **p b 0.005 and ***p b 0.0005, versus controls.
Fig. 9.Hsp27 overexpression reduces CM-induced apoptosis inHREC. HRECwere transfectedwithHsp27 using Superfect Transfection Reagent. Overexpression ofHsp27 after 24 and 48 h
of transfectionwas conﬁrmed byWestern blotting (A). 24 h post-transfection cellswere treatedwith CM1 and CM2 andHG for 48 h as in Fig. 2. Apoptotic cellswere counted after staining
with Hoechst reagent. Data are means ± SD of three independent experiments. *p b 0.05.
Fig. 10.A conceptual viewof themechanisms bywhich CMdownregulatesHsp27 inHREC
and bring about apoptosis in diabetes. Inﬂammatory cytokines are upregulated in the
diabetic eye. Inﬂammatory cytokines activate NOS2 and IDO to generate NO and ROS,
respectively, which react to form ONOO•. The ONOO•, by an unknown mechanism,
downregulates Hsp27 and brings about apoptosis of HREC. IFGNR = IFN-γ receptor1,
ILR = IL-1β receptor, and TLR, TNF-α receptor.
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nitrite levels in the culture medium (Fig. 5B). Whether the increased
production of NO was responsible for the downregulation of Hsp27
was then tested. The addition of an NO donor, DETA NONOate (in the
absence of cytokines), to the culturemedium increasedNO levels signif-
icantly (Fig. 5C, p b 0.0005), but this increase in NO (in the absence of
CM) had no effect on Hsp27 levels (Fig. 5D). However, the addition of
the NOS inhibitor, L-NAME along with CM and HG prevented Hsp27
downregulation (Fig. 5E, and F). These data suggest that CM increase
NO production in HREC during downregulation of Hsp27, but NO
alone is not responsible for such downregulation.
3.6. Peroxynitrite downregulates Hsp27 in HREC
From the above ﬁndings, it is clear that neither ROS nor NO alone is
responsible for the cytokine-mediated downregulation of Hsp27 in
HREC. We hypothesized that the downregulation of Hsp27 could be
due to peroxynitrite radical (ONOO•) produced from the reaction of
NO and superoxide. We tested this by adding a ONOO• donor, SIN-1,
to the culture media. We found a slight but statistically insigniﬁcant
drop in the Hsp27 levels by this treatment (Fig. 6A). However, direct
treatment with peroxynitrite had a signiﬁcant inhibitory effect on
Hsp27 expression, which was time-dependent (p b 0.05, Fig. 6B). We
then checked the possibility that ONOO• downregulated HSF-1 and
thus reduced Hsp27 levels. Treatment with peroxynitrite had no effect
on cytosolic (Fig. 6C) or nuclear levels (Fig. 6D) of Hsp27. We then test-
edwhether ONOO• affected the binding of HSF-1 to DNAusing an EMSA.
The results in Fig. 6E showed that direct addition of peroxynitrite had no
effect on the binding of HSF-1 to DNA.
To further examine the role of ONOO•, we used L-NAME together
with TEMPOL (to block NO production and ROS sequestration, respec-
tively) in the culture medium. The cytokine-mediated reduction in
Hsp27 level (seen in Fig. 2) was prevented by these two reagents
(Fig. 7A). Addition of TEMPOL and L-NAME resulted in inhibition of
ROS and NO in CM ± HG-treated cells (Fig. 7B, C, compare results in
Figs. 4E and 5B). In fact, the treatment of L-NAME + TEMPOL resulted
in ROS levels falling below the basal levels found in untreated (control)
cells (Fig. 7B). These results conﬁrm the causal role of ONOO• in the
Hsp27 downregulation by CM in HREC.
3.7. Downregulation of Hsp27 leads to apoptosis of HREC
Hsp27 is an anti-apoptotic protein, and thus its downregulation by
cytokines could lead to apoptosis of HREC. To test this, wemeasured ap-
optotic cells in the cytokine (±HG)-treated cells. Treatment with CM1
resulted in ~14% apoptotic cells (p b 0.05), which increased to ~24%
with CM2 (Fig. 8A). While HG treatment alone showed ~16% apoptoticcells (7% more than controls, p b 0.005), the combination of LC and HG
showed 2.5-fold more apoptotic cells than seen with LC alone (Fig. 8B,
p b 0.0005). These treatments resulted in signiﬁcant increases in
caspase-3 activity (p b 0.0005, Fig. 8C). To further assess the role of
Hsp27, we treated HREC with an siRNA for Hsp27. siRNA treatment re-
sulted in a signiﬁcant (p b 0.0005) ~90% downregulation of Hsp27
(Fig. 8D). Scrambled siRNA did not show a similar effect. This siRNA
treatment resulted in a signiﬁcant increase in apoptosis of HRECs
(Fig. 8E, p b 0.005). The role of ROS andNO in cytokine-induced apopto-
sis of HREC was investigated further. The CM-induced apoptosis was
largely prevented by the MT and L-NAME treatments (Fig. 8F, G). Fur-
thermore, the addition of SIN-1 at 2 mM caused a signiﬁcant increase
in apoptosis of HRECs (p b 0.0005, Fig. 8H). Together, these data suggest
that downregulation of Hsp27 by ONOO•. results in apoptosis of HRECs.
To test whether overexpression of Hsp27 offered protection against
cytokine-induced apoptosis, we transfected HREC with human Hsp27.
Transfected cells showed 15 and 20% increase in Hsp27 after 24 and
48 h (Fig. 9A). After 24 h of transfection, cells were treated with CM1
and CM2 ± HG for 48 h. Unlike non-transfected cells that showed 13
173R.B. Nahomi et al. / Biochimica et Biophysica Acta 1842 (2014) 164–174and 22% apoptotic cells with CM1 and CM2 treatments (Fig. 8), Hsp27
overexpressing cells showed only 8 and 9% apoptotic cells (Fig. 9B).
Hsp27 overexpression also mitigated the effect of cytokines + HG.
These results further support the notion that a reduction in Hsp27 is
central to cytokine-mediated apoptosis of HREC.
4. Discussion
Our initial experiments showed that HREC contained several small
heat shock proteins, including Hsp27 (data not shown). We expected
Hsp27 to be upregulated by the cytokine and HG treatments because
they can impose signiﬁcant cellular stress. However, we found that a
combination of pro-inﬂammatory cytokines downregulated Hsp27
and HG exacerbated such an effect. Interestingly, individual cytokines,
when tested separately, did not elicit a similar response. That the re-
sponse occurred only when all three cytokines (TNF-α, IL-1β, IFN-γ)
were present simultaneously suggests a synergistic cooperativemecha-
nism in the Hsp27 downregulation. Similar synergy has been observed
during cytokine-mediated apoptosis of corneal endothelial cells [32], al-
though the mechanism(s) of such synergistic actions remain unknown.
Additionally, our data showed that S82 phosphorylation in Hsp27 was
reduced by treatment of HREC with CM and HG. S82 is a major site for
phosphorylation in Hsp27, mediated by p38MAPK/MAPKAK-2. Phos-
phorylation of Hsp27 changes its tertiary structure from a polymeric
to predominantly dimeric [33]. Phosphorylation is required for the
anti-apoptotic function of Hsp27 [reviewed in [34]].Whether the down-
regulation of S82 phosphorylation is due to adverse effects of cytokines
on the upstream kinases needs to be determined. That CM neither re-
duced the total or nuclear HSF-1 levels nor its binding to DNA points
to other mechanisms in Hsp27 downregulation (see below).
Our data showed that the CM induced IDO in HREC and that this in-
duction resulted in the activation of the kynurenine pathway and, con-
sequently, the formation of ROS. Previous studies have also shown that
kynurenines can produceROS in cells [29,35]. The ability ofMT to inhibit
ROS production and simultaneously block cytokine-mediated downreg-
ulation of Hsp27 points to an important role for ROS. However, addition
of kynurenine to culture media, which can increase intracellular ROS
[35], failed to downregulate Hsp27, indicating that ROS produced by
CM treatment is necessary but insufﬁcient to downregulate Hsp27.
Our data showed that CMupregulatedNOS2 and increasedNO levels
in HREC. To test whether NO was involved in Hsp27 downregulation,
we tested the effect of a NO donor on HREC. Although it did result in
high NO levels, this treatment failed to downregulate Hsp27, suggesting
the possibility that ONOO•, formed from the reaction of NO with super-
oxide, is responsible for the downregulation of Hsp27. In fact, addition
of ONOO• to the culture medium decreased Hsp27 levels, similar to
CM, conﬁrming that ONOO• downregulated Hsp27. ONOO• has been
linked to inﬂammation-mediated damage in cells and tissues and
apoptosis [36]. However, the mechanism of such apoptosis is not clear.
Protein nitration, which has been shown to be increased in the diabetic
retina, is a consequence of increased ONOO [37].Whether protein nitra-
tion contributes to the cytokine-mediatedHsp27downregulation needs
to be investigated further.
The CM brought about apoptosis of HREC, and Hsp27 downregula-
tion appeared to be a keymechanism in this apoptosis. The requirement
of Hsp27 for HREC viability was further reiterated by our data, showing
that depletion of Hsp27 by siRNA lead to apoptosis in HREC. Previous
studies have shown that hyperglycemia-mediated inﬂammatory cyto-
kines cause apoptosis in retinal capillary cells [38,39], although the
mechanisms are still unclear. The present study provides a mechanistic
link between inﬂammatory cytokines and apoptosis, through ONOO•
formation and downregulation of Hsp27. Hsp27 inhibits apoptosis by
several mechanisms, including binding to cytochrome c, activating Akt
and blocking caspase-3 activation [40]. Whether a decrease in these
functions as a consequence of a reduction in Hsp27 activity leads to
apoptosis of HREC remains to be shown. Moreover, whether Hsp27 isdownregulated in endothelial cells of diabetic retina is unknown. There
is evidence for upregulation of heat shock proteins in general and the spe-
ciﬁc upregulation of Hsp27 in the diabetic retina [31,41,42]. It is possible
that there may be an overall increase in these proteins in diabetic retina,
but at the same time locally within capillary endothelial cells, there may
be a decrease. Further studies are needed to examine this. A schematic
representation of the possible mechanisms by which CM may bring
about apoptosis of HREC is shown in Fig. 10.
In summary, we showed that Hsp27 is required for HREC viability
and its decrease through an upregulation of inﬂammatory cytokines
and ONOO• formation could be a mechanism in acellular capillary
formation in the early phase of diabetic retinopathy, reinforcing the
idea that anti-inﬂammatory agents could be of therapeutic beneﬁt in
diabetic retinopathy.
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